BRIEF-Bausch + Lomb and Nicox announce publication of LBN ophthalmic solution 0.024% phase 3 study results

Wed Jul 6, 2016 1:35am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

July 6 (Reuters) - Nicox SA :

* Bausch + Lomb and Nicox announce publication of latanoprostene bunod (LBN) ophthalmic solution 0.024 pct phase 3 study results in American journal of ophthalmology

* Second published phase 3 trial to demonstrate significantly greater efficacy versus. Timolol maleate 0.5 pct Source text for Eikon: Further company coverage: (Gdynia Newsroom)